Our recent publication reveals the remarkable efficacy of iPLUS in a diverse array of expression platforms and in the yield of Trastuzumab, Spike and MAGEC2, a tumor-specific antigen tested for cancer mRNA vaccines.
February 29, 2024by iPLUS
HomeAuthor
iPLUS
During last week we attended #websummit2022 🚀 to promote iPLUS! Thank you to the RESOLVE-Health for allowing us to have this fantastic experience. #iPLUSbiosciences
